Tânia M T Guimarães, Tânia Moniz, Cláudia Nunes, Maya Margaritova Zaharieva, Mila Kaleva, Krassimira Yoncheva, Hristo Najdenski, Sofia A Costa Lima, Salette Reis
In the last years, microneedles (MNs) have been considered a valuable, painless, and minimally invasive approach for controlled transdermal drug delivery (TDD). Rivastigmine (RV), a drug administered to patients suffering from dementia, is currently delivered by oral or transdermal routes; however, both present limitations, mainly gastrointestinal adverse symptoms or local skin irritation and drug losses, respectively, for each route. Given this, the objective of the present work was to develop and evaluate the potential of polymeric MNs for RV transdermal delivery in a controlled manner...
March 30, 2022: Pharmaceutics